- Home
- KURA vs DFIN Comparison
KURA vs DFIN Comparison
Compare KURA & DFIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KURA | DFIN |
|---|---|---|
| Founded | 2014 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Other Consumer Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | 2015 | 2017 |
Fundamental Metrics
Financial Performance| Metric | KURA | DFIN |
|---|---|---|
| Price | $13.03 | $48.90 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 2 |
| Target Price | $25.56 | ★ $61.50 |
| AVG Volume (30 Days) | ★ 2.2M | 171.1K |
| Earning Date | 05-12-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.72 |
| Revenue | $67,482,000.00 | ★ $963,000,000.00 |
| Revenue This Year | $28.28 | $4.98 |
| Revenue Next Year | $106.37 | $3.87 |
| P/E Ratio | ★ N/A | $17.93 |
| Revenue Growth | ★ 25.24 | N/A |
| 52 Week Low | $7.36 | $36.11 |
| 52 Week High | $13.90 | $56.26 |
Technical Indicators
Market Signals| Indicator | KURA | DFIN |
|---|---|---|
| Relative Strength Index (RSI) | 64.67 | 54.59 |
| Support Level | $7.96 | $45.09 |
| Resistance Level | $13.90 | $50.64 |
| Average True Range (ATR) | 0.68 | 1.42 |
| MACD | 0.09 | -0.08 |
| Stochastic Oscillator | 73.57 | 54.63 |
Price Performance
Historical ComparisonAbout KURA Kura Oncology Inc.
Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.
About DFIN Donnelley Financial Solutions Inc.
Donnelley Financial Solutions Inc is a risk and compliance software solutions and related services provider. The company provides regulatory filing and deal solutions via its software-as-a-service, technology-enabled services, and print and distribution solutions to public and private companies, mutual funds, and other regulated investment firms. It operates in four reportable segments: Capital Markets - Software Solutions, Capital Markets - Compliance and Communications Management (its key revenue-generating segment), Investment Companies - Software Solutions, and Investment Companies - Compliance and Communications Management. Its geographical segments are the United States (USA), Europe, Asia, Canada, and Others, of which the USA accounts for the vast majority of its total revenue.